Repligen and Medpace were cited alongside Monster Beverage and Microsoft as thematic investing winners in the drug development inputs segment.
3 reports, 1 independent
Updated Jul 27
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Repligen and Medpace were cited alongside Monster Beverage and Microsoft as thematic investing winners in the drug development inputs segment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Monster Beverage
American beverage company
-
Microsoft
American multinational technology corporation
- Nvidia is expanding its platform deployment across major cloud providers, including Google Cloud and Microsoft Azure.
- Cloud giants, including Microsoft, Amazon, Anthropic, OpenAI, and Google, are benefiting from overall AI market growth while navigating corporate cost containment and future market competition.
-
Repligen
bioTech Company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- StockStoryRepligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before the bell. H